AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Porcine xenografts for human organ transplantation

Summary

Xenotransplantation, or transplantation of animal-derived organs or tissues, is a potential solution to the worldwide shortage of donor organs. In particular, the pig is regarded as a favorable species for clinical transplantation into humans because of greater availability, similarity in organ size, and reduced risk of infections. However, hyperacute rejection of xenografts, in which the foreign donor tissue is destroyed by the recipient’s immune response, remains a critical barrier to xenotransplantation. This technology describes transgenic pigs that lack the expression of α(1-3)-galactosyltransferase (GalT), an enzyme that produces one of the primary antigens that trigger hyperacute rejection. By inhibiting the production of this epitope, this technology potentially enables the transplantation of porcine tissue into humans without the risk of hyperacute rejection.

Technology Benefits

Decreased immunologic response and risk of rejection following xenotransplantationDecreased need for immunosuppressive therapy post-transplantationPatent Information:Patent Issued (US 6,153,428)Patent Issued (US 6,413,769)Tech Ventures Reference: IR Proxy73

Technology Application

Xenografts for patients needing organ and tissue transplantsCells and tissue for xenotransplantation researchTransplant models for surgical training

Detailed Technology Description

None

Country/Region

USA

For more information, please click Here